

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB—Continued

Title of collection	OMB control No.	Date approval expires
Focus Groups About Drug Products as Used by the Food and Drug Administration .....	0910-0677	5/31/2020
Testing Communication on Medical Devices and Radiation-Emitting Products .....	0910-0678	5/31/2020
Tracking Network for PETNet, LivestockNet, and SampleNet .....	0910-0680	5/31/2020
Medical Devices: Pediatric Uses of Devices; Requirements for Submission of Information on Pediatric Subpopulations That Suffer From a Disease or Condition That a Device is Intended to Treat, Diagnose, or Cure .....	0910-0748	5/31/2020
Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics .....	0910-0765	5/31/2020
Superimposed Text in Direct-to-Consumer Promotion of Prescription Drugs .....	0910-0831	5/31/2020

Dated: June 27, 2017.

**Anna K. Abram,**  
Deputy Commissioner for Policy, Planning,  
Legislation, and Analysis.

[FR Doc. 2017-13890 Filed 6-30-17; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Meeting of the Secretary’s Advisory Committee on Human Research Protections**

**AGENCY:** Office of the Secretary, Office of the Assistant Secretary for Health, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** Pursuant to Section 10(a) of the Federal Advisory Committee Act, notice is hereby given that the Secretary’s Advisory Committee on Human Research Protections (SACHRP) will hold a meeting that will be open to the public. Information about SACHRP and the full meeting agenda will be posted on the SACHRP Web site at: <http://www.dhhs.gov/ohrp/sachrp-committee/meetings/index.html>.

**DATES:** The meeting will be held on Tuesday, July 25, 2017, from 8:30 a.m. until 5:00 p.m., and Wednesday, July 26, 2017, from 8:30 a.m. until 2:30 p.m.

**ADDRESSES:** Fishers Lane Conference Center, Terrace Level, 5635 Fishers Lane, Rockville, Maryland 20852.

**FOR FURTHER INFORMATION CONTACT:** Julia Gorey, J.D., Executive Director, SACHRP, U.S. Department of Health and Human Services, 1101 Wootton Parkway, Suite 200, Rockville, Maryland 20852; telephone: 240-453-8141; fax: 240-453-6909; email address: [SACHRP@hhs.gov](mailto:SACHRP@hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under the authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, SACHRP was established to provide expert advice and recommendations to the Secretary of Health and Human Services, through the Assistant Secretary for Health, on

issues and topics pertaining to or associated with the protection of human research subjects.

The Subpart A Subcommittee (SAS) was established by SACHRP in October 2006 and is charged with developing recommendations for consideration by SACHRP regarding the application of subpart A of 45 CFR part 46 in the current research environment.

The Subcommittee on Harmonization (SOH) was established by SACHRP at its July 2009 meeting and charged with identifying and prioritizing areas in which regulations and/or guidelines for human subjects research adopted by various agencies or offices within HHS would benefit from harmonization, consistency, clarity, simplification and/or coordination.

The SACHRP meeting will open to the public at 8:30 a.m., on Tuesday, July 25, 2017, followed by opening remarks from Dr. Jerry Menikoff, Director, Office for Human Research Protections and Dr. Stephen Rosenfeld, SACHRP Chair. (<https://www.gpo.gov/fdsys/pkg/FR-2017-01-19/html/2017-01058.htm>).

The SOH will present their recommendations regarding the new Common Rule’s compliance dates and transition provisions, as well as for the interpretation and implementation of the broad consent provision, followed by the SAS discussing their report on the interpretation of the new exemption involving benign behavioral interventions. The Tuesday, July 25, meeting will adjourn at approximately 5:00 p.m.

The Wednesday, July 26, meeting will begin at 8:30 a.m. with discussion of recommendations from the SAS regarding the new Common Rule’s expedited review requirements.

The meeting will adjourn at approximately 2:30 p.m., July 26, 2017. Time for public comment sessions will be allotted both days. On-site registration is required for participation in the live public comment session. Note that public comment must be relevant to issues currently being addressed by the SACHRP. Individuals submitting written statements as public

comment should email or fax their comments to SACHRP at [SACHRP@hhs.gov](mailto:SACHRP@hhs.gov) at least five business days prior to the meeting.

Public attendance at the meeting is limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify one of the designated SACHRP points of contact at the address/phone number listed above at least one week prior to the meeting.

Dated: June 27, 2017.

**Julia G. Gorey,**  
Executive Director, Secretary’s Advisory Committee on Human Research Protections.

[FR Doc. 2017-13932 Filed 6-30-17; 8:45 am]

**BILLING CODE 4150-36-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Public Stakeholder Listening Session on Strategies for Improving Parity for Mental Health and Substance Use Disorder Coverage**

**AGENCY:** Assistant Secretary for Planning and Evaluation, HHS.

**ACTION:** Notice of meeting.

**SUMMARY:** This notice announces a public stakeholder listening session on Strategies for Improving Parity for Mental Health and Substance Use Disorder Coverage. The public meeting, mandated in the 21st Century Cures Act, seeks public comment on improved Federal and State coordination related to section 2726 of the Public Health Service Act, section 712 of the Employee Retirement Income Security Act of 1974, section 9812 of the Internal Revenue Code of 1986, and any comparable provisions of State law. The public meeting will seek participation from the required stakeholders in statute, State health commissioners, State agencies, State attorneys general, the National Association of Insurance Commissioners, health insurance issuers, providers of mental health and

substance use disorder treatment, employers, and patients or their advocates. Written comments may be submitted to [parity@hhs.gov](mailto:parity@hhs.gov) for two weeks prior to the meeting through August 10, 2017.

**DATES:** The meeting will be held on July 27, 2017 from 9:30 a.m. to 11:30 a.m. EDT.

**ADDRESSES:** The meeting will be held in the first floor auditorium in the Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201.

*Comments:* The time for oral comments will be limited to five (5) minutes per individual. In lieu of oral comments, formal written comments may be submitted for the record to Laurel Fuller, ASPE, 200 Independence Avenue SW., Room 424E, Washington, DC 20201; all comments should be submitted to [parity@hhs.gov](mailto:parity@hhs.gov). Those submitting comments should identify themselves and any relevant organizational affiliations.

**FOR FURTHER INFORMATION CONTACT:** Laurel Fuller (202) 690-5949, [Laurel.Fuller@hhs.gov](mailto:Laurel.Fuller@hhs.gov).

**SUPPLEMENTARY INFORMATION:**

*Procedure and Agenda:* This meeting is open to the public. Please allow 45 minutes to go through security and walk to the meeting room. The meeting will also be webcast at [www.hhs.gov/live](http://www.hhs.gov/live).

*Note:* Seating will be limited to 75 attendees; this listening session will also be webcast online at [www.hhs.gov/live](http://www.hhs.gov/live). Those wishing to attend the meeting must send an email to [parity@hhs.gov](mailto:parity@hhs.gov) and put "July 27 Public Meeting" in the Subject line by Friday, July 21, 2017 so that their names may be put on a list of expected attendees and forwarded to the security officers the Humphrey Building. In the email please also indicate which group you are representing (State health commissioners, State agencies, State attorneys general, the National Association of Insurance Commissioners, health insurance issuers, providers of mental health and substance use disorder treatment, employers, and patients or their advocates; or other). Any interested member of the public who is a non-U.S. citizen should include this information at the time of registration to ensure that the appropriate security procedure to gain entry to the building is carried out. Although the meeting is open to the public, procedures governing security and the entrance to federal buildings may change without notice. If you wish to make a public comment, you must note that within your email.

**Authority:** 114-255 Pub. L. 114-255.

Dated: June 26, 2017.

**John R. Graham,**

*Acting Assistant Secretary for Planning and Evaluation.*

[FR Doc. 2017-13959 Filed 6-30-17; 8:45 am]

**BILLING CODE 4150-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Review of K24 Application.

*Date:* July 25, 2017.

*Time:* 11:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Barbara A. Woynarowska, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 754, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 402-7172, [woynarowskab@nidk.nih.gov](mailto:woynarowskab@nidk.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; PAR-16-127: NIDDK Program Projects (P01).

*Date:* August 7, 2017.

*Time:* 1:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-594-2242, [jerkinsa@nidk.nih.gov](mailto:jerkinsa@nidk.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases

Special Emphasis Panel; Limited Competition: Data Coordinating Center for Type 1 Diabetes TrialNet (UC4).

*Date:* August 15, 2017.

*Time:* 1:00 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Paul A. Rushing, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8895, [rushingp@extra.nidk.nih.gov](mailto:rushingp@extra.nidk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: June 27, 2017.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017-13896 Filed 6-30-17; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, July 12, 2017, 11:00 a.m. to July 12, 2017, 3:00 p.m., National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, 7W114, Rockville, MD 20850 which was published in the **Federal Register** on May 31, 2017, 82 FR 24983.

The meeting notice is amended to change the meeting title to "Biospecimen and Innovative Technology". The meeting is closed to the public.

Dated: June 27, 2017.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017-13895 Filed 6-30-17; 8:45 am]

**BILLING CODE 4140-01-P**